Riding a 3-game win streak, the Bengals cling to playoff hopes with the Broncos next'We need new leadership': Atlantic Liberal caucus calls for Trudeau's resignationTEL AVIV, Israel (AP) — Israeli Prime Minister Benjamin Netanyahu underwent successful surgery Sunday to have his prostate removed, hospital officials said, a procedure that came as he manages multiple crises including the war in Gaza and his trial for alleged corruption . Netanyahu, who has had a series of health issues in recent years, has gone to great lengths to bolster a public image of himself as a healthy, energetic leader. During his trial this month, he boasted about working 18-hour days, accompanied by a cigar. But as Israel's longest-serving leader, such a grueling workload over a total of 17 years in power could take a toll on his well-being. Netanyahu, 75, is among older world leaders including U.S. President Joe Biden, 82 , President-elect Donald Trump, 78 , Brazil's President Luiz Inácio Lula da Silva , 79, and Pope Francis , 88, who have come under scrutiny for their age and health issues. Netanyahu's latest condition is common in older men, but the procedure has had some fallout. The judges overseeing his trial accepted a request from his lawyer on Sunday to call off three days of testimony scheduled this week. The lawyer, Amit Hadad, had argued that Netanyahu would be fully sedated for the procedure and hospitalized for “a number of days.” Dr. Ofer Gofrit, head of the urology department at Jerusalem's Hadassah Medical Center, said in a video statement late Sunday that the procedure had gone well and “there was no fear” of cancer or malignancy. “We only hope for the best,” he said. In a statement, Netanyahu thanked his doctors. His office said he was "fully alert" and was taken to an underground recovery unit fortified against potential missile attacks. Netanyahu was expected to remain in the hospital for several days of observation. Justice Minister Yariv Levin, a close ally, served as acting prime minister during the operation. With so much at stake, Netanyahu’s health in wartime is a concern for both Israelis and the wider world. As Israel’s leader, Netanyahu is at the center of major global events that are shifting the Middle East . With the dizzying pace of the past 14 months, being incapacitated for even a few hours can be risky. Netanyahu will be in the hospital at a time when international mediators are pushing Israel and Hamas to reach a ceasefire in Gaza and as fighting between Israel and Yemen’s Iran-backed Houthi rebels intensifies . Prostate issues are common and in many cases easily treatable. Still, the procedure puts a dent in Netanyahu’s image of vigor at a time when he would want to project strength more than ever, both to an Israeli audience navigating constant threats as well as to Israel’s enemies looking to expose its weaknesses. Netanyahu insists he is in excellent health. His office releases footage of him touring war zones in full protective gear flanked by military officers, or meeting with defense officials on windswept hilltops in youthful dark shades and puffer jackets. But that image was shattered last year when Netanyahu’s doctors revealed that he had a heart condition , a problem that he had apparently long known about but concealed from the public. A week after a fainting spell, Netanyahu was fitted with a pacemaker to control his heartbeat. Only then did staff at the Sheba Medical Center reveal that Netanyahu has for years experienced a condition that can cause irregular heartbeats. The revelation came as Netanyahu was dealing with massive anti-government protests. The news about a chronic heart problem stoked further anger and distrust during extreme political polarization in Israel. Last year, Netanyahu was rushed to the hospital for what doctors said likely was dehydration . He stayed overnight, prompting his weekly Cabinet meeting to be delayed. Earlier this year, Netanyahu underwent hernia surgery , during which he was under full anesthesia and unconscious. Levin served as acting prime minister during the operation. According to Netanyahu’s office, the Israeli leader was diagnosed with a urinary tract infection on Wednesday stemming from a benign enlargement of his prostate. The infection was treated successfully with antibiotics, but doctors said the surgery was needed in any case. Complications from prostate enlargement are common in men in their 70s and 80s, Dr. Shay Golan, head of the oncology urology service at Israel’s Rabin Medical Center, told Israeli Army Radio. Golan spoke in general terms and was not involved in Netanyahu’s care or treatment. He said an enlarged prostate can block proper emptying of the bladder, leading to a build-up of urine that can lead to an infection or other complications. After medicinal treatment, doctors can recommend a procedure to remove the prostate to prevent future blockages, Golan said. In Netanyahu’s case, because the prostate is not cancerous, Golan said doctors were likely performing an endoscopic surgery, carried out by inserting small instruments into a body cavity, rather than making surgical cuts in the abdomen to reach the prostate. The procedure lasts about an hour, Golan said, and recovery is quick. He said that aside from catheter use for one to three days after the procedure, patients can return to normal activity without significant limitations. AP correspondent Isaac Scharf contributed reporting.

Amazon founder Jeff Bezos and Lauren Sanchez are not having a $600 million wedding in Aspen, US, this weekend. Late last week, some reports claimed that billionaire Bezos will marry his fiance Lauren Sanchez next Saturday in an extravagant $600 million wedding in Aspen, Colorado. An upset Bezos has strongly denied the extravagant plans. Amazon's former CEO was so angry with the report that he took to social media platform X, formerly Twitter, to clarify. And what makes this clarification serious is the fact that Bezos is not a regular on Twitter. "Furthermore, this whole thing is completely false — none of this is happening. The old adage “don’t believe everything you read” is even more true today than it ever has been. Now lies can get ALL the way around the world before the truth can get its pants on. So be careful out there folks and don’t be gullible. Will be interesting to see if all the outlets that “covered” and re-reported on this issue a correction when it comes and goes and doesn’t happen," Bezos wrote. Elon Musk's 'comforting' reply Tesla and SpaceX CEO Elon Musk, who is widely known to share a frosty relationship with Bezos, replied to Bezos' angry post. "That said, I hope you do hold an epic wedding. It’s nice to know that epic events are happening somewhere in the world, even if one is not present. A world where there are amazing events somewhere is better than a world where they are happening nowhere," wrote Musk in a post seemingly aimed at comforting Bezos. No wedding dates confirmed The Daily Mail was the first to report the $600 million wedding plan quoting a “well-placed source.” The report was then picked up by the New York Post. Billionaire Bill Ackman then quote-tweeted a now-deleted post from New York Post writing, “This is not credible. Unless you are buying each of your guests a house, you can’t spend this much money.” Ackman's tweet was what Jeff Bezos quoted in his reply. Incidentally, Bezos, 60, and his fiance, 54, have so far remained mum on their wedding plans and have not yet publicly confirmed their wedding date.Georgia is turning to backup Gunner Stockton at quarterback in CFP quarterfinal against Irish

Sprouts Farmers Market SFM has outperformed the market over the past 5 years by 32.99% on an annualized basis producing an average annual return of 45.92%. Currently, Sprouts Farmers Market has a market capitalization of $12.93 billion. Buying $100 In SFM: If an investor had bought $100 of SFM stock 5 years ago, it would be worth $654.85 today based on a price of $129.31 for SFM at the time of writing. Sprouts Farmers Market's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. FATE , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company's FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. "We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation," said Bob Valamehr, President of Research and Development of Fate Therapeutics. "We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization." FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company's FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study's conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled " Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ", the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled " Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ", the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics' iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company's iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company's clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company's product candidates, the timing and availability of data from the Company's clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, the Company's clinical and product development strategy, and the Company's expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.( MENAFN - GetNews) Heritage of Excellence, Advancing with Honor. On November 25, the highly anticipated 15th Annual Construction Machinery Brand Ceremony was grandly held in Shanghai. During the event, the 2024 Top 10 Rankings of the Construction Machinery Industry were officially released. This prestigious conference honored the influential brands and outstanding products that emerged over the past year. By setting exemplary benchmarks for the industry, the event aims to promote industrial prosperity, foster innovation, and drive transformative development across the sector. Amid the overlapping trends of a new global energy revolution and deep technological innovation, the construction machinery industry is accelerating its transformation toward high-end, intelligent, and green development. Product lines for primary machinery have become increasingly diverse, with continuous improvements in quality and performance. Guided by industrial policies aimed at supplementing, strengthening, and extending supply chains, significant progress has been made in key core component technologies, providing robust support for collaborative development between primary and supporting enterprises, as well as for the industry's quality improvement and upgrading. At the same time, the vast stock market of existing equipment, combined with the push for large-scale equipment upgrades, has spurred new focus and positioning in aftermarket operations, including equipment leasing, spare parts distribution, maintenance services, and the trading of second-hand equipment. This selection process adhered to principles of rigor, authority, fairness, and objectivity. After three stringent rounds of evaluation-online voting, user scoring, and expert review-a new cohort of outstanding enterprises and products in the fields of machinery, components, and industry user applications emerged. These exemplary winners set a benchmark for the continued growth and innovation of the construction machinery industry. Click the link to view the complete list of award-winning companies. Adhering to the principle of "Building Brands, Strengthening Technology, and Shaping the Power and Value of Enterprises," the Brand Ceremony has been held for 15 consecutive years. It has consistently exerted remarkable influence within the industry, serving as a driving force for its development and earning widespread acclaim and support from industry professionals. Each edition of the Brand Ceremony aligns closely with the pulse of the times, celebrating the spirit of exceptional brands while inspiring numerous enterprises to pursue paths of branding and high-end development. The release of the industry rankings highlights the industry's recognition of companies' core technological capabilities and innovative product strength. This not only empowers enterprises with the "wings to soar" in their brand development but also injects fresh vitality into the sustainable growth of China's construction machinery industry! MENAFN23122024003238003268ID1109025386 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Yes, That Viral LinkedIn Post You Read Was Probably AI-GeneratedPresident-elect Donald Trump has once again suggested he wants to revert the name of North America’s tallest mountain — Alaska's Denali — to Mount McKinley, wading into a sensitive and decades-old conflict about what the peak should be called. Former President Barack Obama changed the official name to Denali in 2015 to reflect the traditions of Alaska Natives as well as the preference of many Alaska residents. The federal government in recent years has endeavored to change place-names considered disrespectful to Native people. “Denali” is an Athabascan word meaning “the high one" or “the great one.” A prospector in 1896 dubbed the peak “Mount McKinley” after President William McKinley, who had never been to Alaska. That name was formally recognized by the U.S. government until Obama changed it over opposition from lawmakers in McKinley's home state of Ohio. Trump suggested in 2016 that he might undo Obama's action, but he dropped that notion after Alaska's senators objected. He raised it again during a rally in Phoenix on Sunday. “McKinley was a very good, maybe a great president,” Trump said Sunday. “They took his name off Mount McKinley, right? That’s what they do to people.” Once again, Trump's suggestion drew quick opposition within Alaska. “Uh. Nope. It’s Denali,” Democratic state Sen. Scott Kawasaki posted on the social platform X Sunday night. Republican Sen. Lisa Murkowski , who for years pushed for legislation to change the name to Denali, conveyed a similar sentiment in a post of her own. “There is only one name worthy of North America’s tallest mountain: Denali — the Great One,” Murkowski wrote on X. Various tribes of Athabascan people have lived in the shadow of the 20,310-foot (6,190-meter) mountain for thousands of years. McKinley, a Republican native of Ohio who served as the 25th president, was assassinated early in his second term in 1901 in Buffalo, New York. Alaska and Ohio have been at odds over the name since at least the 1970s. Alaska had a standing request to change the name since 1975, when the legislature passed a resolution and then-Gov. Jay Hammond appealed to the federal government. Known for its majestic views, the mountain is dotted with glaciers and covered at the top with snow year-round, with powerful winds that make it difficult for the adventurous few who seek to climb it. Rush reported from Portland, Oregon.Douglas Emmett, Inc. ( NYSE:DEI – Get Free Report ) declared a quarterly dividend on Tuesday, December 17th, Wall Street Journal reports. Investors of record on Tuesday, December 31st will be paid a dividend of 0.19 per share by the real estate investment trust on Wednesday, January 15th. This represents a $0.76 annualized dividend and a dividend yield of 4.08%. The ex-dividend date is Tuesday, December 31st. Douglas Emmett has raised its dividend payment by an average of 10.3% per year over the last three years. Douglas Emmett has a dividend payout ratio of -400.0% indicating that the company cannot currently cover its dividend with earnings alone and is relying on its balance sheet to cover its dividend payments. Equities research analysts expect Douglas Emmett to earn $1.50 per share next year, which means the company should continue to be able to cover its $0.76 annual dividend with an expected future payout ratio of 50.7%. Douglas Emmett Trading Down 1.9 % NYSE:DEI opened at $18.63 on Friday. Douglas Emmett has a one year low of $12.35 and a one year high of $20.50. The company’s 50-day simple moving average is $18.86 and its 200 day simple moving average is $16.70. The firm has a market capitalization of $3.12 billion, a P/E ratio of -186.30 and a beta of 1.11. The company has a debt-to-equity ratio of 1.51, a current ratio of 4.09 and a quick ratio of 4.09. Wall Street Analyst Weigh In A number of equities analysts have recently issued reports on DEI shares. Scotiabank upgraded Douglas Emmett from a “sector perform” rating to a “sector outperform” rating and raised their price target for the stock from $16.00 to $21.00 in a research note on Thursday, November 14th. Citigroup raised their target price on Douglas Emmett from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, September 12th. Evercore ISI upped their price target on shares of Douglas Emmett from $16.00 to $19.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Wells Fargo & Company raised their price objective on shares of Douglas Emmett from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, September 11th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Douglas Emmett from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, September 9th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Douglas Emmett has an average rating of “Hold” and a consensus price target of $17.43. View Our Latest Stock Analysis on DEI About Douglas Emmett ( Get Free Report ) Douglas Emmett, Inc (DEI) is a fully integrated, self-administered and self-managed real estate investment trust (REIT), and one of the largest owners and operators of high-quality office and multifamily properties located in the premier coastal submarkets of Los Angeles and Honolulu. Douglas Emmett focuses on owning and acquiring a substantial share of top-tier office properties and premier multifamily communities in neighborhoods that possess significant supply constraints, high-end executive housing and key lifestyle amenities. Recommended Stories Receive News & Ratings for Douglas Emmett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Douglas Emmett and related companies with MarketBeat.com's FREE daily email newsletter .